Sign inJoin waitlistJoin the waitlist

Patricia Baxter

Director, Clinical Research Operations, Cancer and Hematology Center · Baylor College of Medicine

Credentials: · · · ·

History

Clinical Research Operations · Baylor College of Medicine
Present
Baylor College of Medicine
Present

Research

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial
The Lancet Oncology · 2019 · 409 citations
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
Nature Medicine · 2024 · 168 citations
Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design
Cell Reports · 2019 · 135 citations

Jack Su
29 papers
Murali Chintagumpala
21 papers
Holly Lindsay
17 papers
AA
Adekunle Adesina
16 papers
SZ
Sibo Zhao
12 papers · 2 as a fellow
Maryam Fouladi
11 papers
CL
Ching Lau
10 papers
Ira Dunkel
9 papers
Susan Blaney
9 papers
WT
Wan Yee Teo
9 papers
Arnold Paulino
8 papers
Lindsay Kilburn
8 papers

Clinical trials

Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
Principal investigator · Completed · Phase 1, Phase 2
National Cancer Institute (NCI)
2012–2018
A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma
Study chair · Active not recruiting · Phase 1
Nationwide Children's Hospital
2018–2029
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Site PI · Recruiting · Phase 2
Nationwide Children's Hospital
2024–2030
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Site PI · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2022–2027